Lars Hanan is co-founder and Partner at BroadOak. With over 20 years of corporate finance and mergers and acquisitions experience, Lars Hanan has executed over 100 transactions in a broad range of industries. Prior to BroadOak, Lars built and managed the life sciences advisory business at Mercator Capital. Before joining Mercator Lars headed the M&A Group at ABN AMRO Investment Banking. In addition to heading the U.S. M&A Group, Mr. Hanan was also a member of the firm’s Fairness Opinion Committees and he was also responsible for the firm’s Healthcare M&A practice with particular sector expertise in medical technology and drug discovery tools. Prior to joining ABN AMRO, Lars held senior mergers and acquisitions positions at SG Cowen, Kidder, Peabody and Lehman Brothers where he managed a wide variety of domestic and cross border transactions. Lars currently serves on the board of A&G Pharmaceuticals.
Lars holds a B.A. in Economics from the University of Virginia and an M.B.A. from the J.L. Kellogg School of Management at Northwestern University.
Bill Snider is co-founder and Partner at BroadOak. Mr. Snider has over 20 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners, LLC, a life sciences focused venture capital firm. He invested in over 20 life science companies while at ETP of which more than half were or are now publicly traded. Mr. Snider, at various times, acted as lead investor, board member and chairman for ETP’s portfolio companies. Prior to ETP he was a vice president and portfolio manager at T. Rowe Price. His responsibilities included managing $2 billion of mutual fund and institutional client portfolios. Some of Mr. Snider’s past directorships include Alpha Innotech and Atto Biosciences and he currently serves on the boards of Molecular Transfer and the MdBio Foundation.
Bill holds the Chartered Financial Analyst accreditation, a B.S. in Finance and an M.B.A. from the Wharton School at the University of Pennsylvania.
D. Kyle Wilson
Kyle Wilson is a Partner at BroadOak. With over 15 years of investment banking experience, Kyle’s background includes broad transaction experience in both capital formation and M&A. Prior to BroadOak, Kyle was a Principal at Canaccord Genuity where he led the tools and diagnostics team and completed over $1.4 billion in life sciences transactions. Kyle was also a Vice President at RBC Capital markets where he successfully executed over $700 million in transactions.
Kyle holds a B.S. in Business Administration, a Juris Doctorate and M.B.A., all from the University of Oklahoma.
Tim Johnson is a Partner at BroadOak. He has over 20 years of combined private equity, investment banking and financial advisory experience and is a Board member of Pathology Inc. and is an observer on the Board of Toxicology Holdings (parent company of DrugScan, Inc. and DSI Medical Services). Tim is a founder and General Partner of Mt. Weather Capital and prior to BroadOak, Tim was a founding partner and Managing Director of England & Company, a middle market investment bank located in Washington, D.C. Previously, he was an investment banker at Salomon Smith Barney's Global Mergers & Acquisitions Group and CIBC World Markets, advising clients on M&A transactions in several industries. Tim also worked in the M&A Group at Friedman, Billings, Ramsey & Co. and began his career at Arthur Andersen, where he provided accounting and consulting services.
A Certified Public Accountant, he earned his B.S. in Accounting and his M.B.A. in Finance from the University of Maryland.
Matt McFarland is a Vice President at BroadOak. Prior to joining BroadOak, he worked for Morgan Stanley’s Capital Strategies Group, an investment banking division focused on middle-market mergers and acquisitions. At Morgan Stanley, Matt was responsible for a variety of sell-side activities including financial analysis, valuation, drafting memoranda and due diligence for transactions in the software, media and energy technology sectors. Prior to Morgan Stanley, Mr. McFarland led business development and sales efforts for AirOcare, Inc., a life sciences start up venture. He also was a financial analyst for Computer Sciences Corporation.
Matt holds a B.A. in Economics from Dickinson College and an M.B.A. with a concentration in Finance from the Robert H. Smith School of Business at the University of Maryland.
Stephen Scott is an Analyst at BroadOak. Prior to joining BroadOak, he interned at Novartis Pharmaceuticals in the Integrated Hospital Care business unit where he worked on commercial strategy for a clinical development portfolio as well as multiple product launches. He has additional experience at private equity firms focused on the biopharmaceutical and healthcare IT sectors, as well as academic research experience in microbiology and molecular biology.
Stephen holds a B.S. in Biochemistry from Clemson University and an M.S. Biotechnology from Georgetown University.